Why the study?
It remains controversial whether adjunctive nicorandil treatment provides cardioprotective effects in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Does nicorandil treatment adjunctive to PCI improve functional and clinical outcomes in patients with acute myocardial infarction?
Does nicorandil treatment adjunctive to PCI improve functional and clinical outcomes in patients with acute myocardial infarction?
Nicorandil adjunctive to PCI in AMI patients improves myocardial reperfusion, cardiac function, and reduces major adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
Supports adjunctive nicorandil during PCI for AMI to improve reperfusion and reduce MACE; extends pooled evidence on functional and clinical endpoints.
OBJECTIVE: There is controversy whether nicorandil treatment has cardioprotective effects in patients with acute myocardial infarction (AMI) following percutaneous coronary intervention (PCI). This meta-analysis was conducted to assess the efficacy of nicorandil on functional and clinical outcomes after PCI. METHODS: Systematic databases were searched to retrieve studies that compared the effect of nicorandil with a control group in patients with AMI who underwent PCI. Outcomes related to coronary blood flow, and functional and clinical outcomes were extracted and a meta-analysis was performed. Trial sequential analysis was conducted to estimate the required sample size for statistical power. RESULTS: Twenty-four trials involving 2965 patients with AMI were enrolled. Pooled results showed that nicorandil treatment significantly suppressed the incidence of no-reflow phenomenon and reperfusion arrhythmia after reperfusion, improved the left ventricular ejection fraction and left ventricular end-systolic volume index, and reduced major adverse cardiovascular events and cardiovascular death. Trial sequential analysis confirmed the effect of nicorandil in reducing the incidence of no-reflow phenomenon and follow-up major adverse cardiovascular events in patients with AMI after PCI. CONCLUSION: Our findings suggest that nicorandil treatment adjunctive to reperfusion therapy improves myocardial reperfusion, cardiac function, and clinical outcomes in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: